Early markers of cardiovascular injury in childhood leukaemia survivors treated with anthracycline chemotherapy

Cardio-Oncology

Table 1 Characteristics of the leukaemia survivors

	Survivor (n = 22)
	No.	%
Underlying Diagnosis
Leukaemia	22	100
ALL	15	68
Standard Risk	13
Intermediate Risk	0
High Risk	2
AML	7	32
Standard Risk	6
Intermediate Risk	1
High Risk	0
Treatment
Chemotherapy	20	91
Chemotherapy & HSCT^a	2	9
Treatment Details
Anthracycline Chemotherapy	22	100
Cumulative Anthracycline Dosage
< 100 mg·m²	9	41
100–249 mg·m²	6	27
250–399 mg·m²	7	32

ALL Acute lymphoblastic leukaemia, AML Acute myeloid leukaemia, HSCT Haematopoietic stem cell transplant
^aHSCT was used in the treatment of two AML patients. Total body irradiation was not part of the conditioning schedule

ISSN: 2057-3804